Skip to main content

CYTK

Stock

CYTK

Stock
Health Care
Biotechnology

Performance overview

CYTK Price
Price Chart

Forward-looking statistics

Beta
1.01
Risk
61.59%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Company info

SectorHealth Care
IndustryBiotechnology
Employees505
Market cap$6.1B

Fundamentals

Enterprise value$3.9B
Revenue$19.2M
Revenue per employee
Profit margin-1737.22%
Debt to equity-3.42

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.29
Dividend per share
Revenue per share$0.17
Avg trading volume (30 day)$53M
Avg trading volume (10 day)$55M
Put-call ratio

Macro factor sensitivity

Growth+2.5
Credit+3.5
Liquidity+0.1
Inflation-0.8
Commodities-0.3
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-6.43
Price to sales215.39
P/E Ratio-6.43
Enterprise Value to Revenue203.88
Price to book-15.42

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.

Zacks Investment Research (May 7, 2025)
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's CYTK aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 from September 26.

Benzinga (May 2, 2025)
Cytokinetics CEO on shares soaring, heart drug Aficamten and American heart health

Robert Blum, Cytokinetics CEO, joins 'The Exchange' to discuss the biotech sector, the company's shares soaring on the latest trial of its heart drug, and more.

CNBC Television (December 28, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free